Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Tsai JT
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=1
------>paper_class2=1
------>vol=3
------>confirm_bywho=None
------>insert_bywho=enochlai49
------>Jurnal_Rank=None
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=61
------>medlineContent=
------>unit=000
------>insert_date=20090314
------>iam=2
------>update_date=None
------>author=???
------>change_event=1
------>ISSN=
------>authors_c=
------>score=-3
------>journal_name=Therapeut Radiol Oncol
------>paper_name=Prognostic parameters in malignant glimas
------>confirm_date=None
------>tch_id=083041
------>pmid=19815537
------>page1=49
------>fullAbstract=OBJECTIVE: The clinical course of gastrointestinal stromal tumor (GIST) spans a wide spectrum from a curable disorder to a highly malignant disease that leads to metastasis and death. To develop prognostic modalities for GIST patients, we developed a mouse monoclonal antibody against pfetin, the prognostic value of which has been previously reported. METHODS: The reactivity of the monoclonal antibody against pfetin was examined by western blotting and immunohistochemistry. RESULTS: Western blotting demonstrated that the monoclonal antibody was specific to pfetin. The immunohistochemical study demonstrated that the 5-year disease-free survival rate was 93.2% and 94.5% for GIST patients with pfetin-positive tumors and 70.0% and 80.7% for those with pfetin-negative tumors in the 159 cases from the National Cancer Center Hospital (P < 0.0001) and in the 100 cases from Niigata University Medical and Dental Hospital (P < 0.0001), respectively. Uni- and multivariate analyses revealed that pfetin expression was a powerful prognostic factor among the clinico-pathological parameters examined. CONCLUSIONS: These results establish pfetin as a practical prognostic marker for GIST patients after surgery. Pfetin may also present a novel therapeutic target to prevent recurrence of GIST.
------>tmu_sno=None
------>sno=21533
------>authors2=Lai YL
------>authors3=Yeh CY
------>authors4=Chen YJ
------>authors5=Shau WY
------>authors6=Chung CH, Chang KH
------>authors6_c=
------>authors=Tsai JT
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=NULL
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=1996
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z